Patent ID: 9234902
Filing Date: 2016-01-12
CPC Classification: C12Q,G01N

Claim Text:
1. A method for measuring the effect of a coumarin anticoagulant drug on coagulability in a patient taking said coumarin drug, for the purpose of adjusting a dosage of said drug, which is based on measuring in a test plasma sample from said patient the influence of said anticoagulant drug on the combined activity of only coagulation factors II and X, the method comprising: providing said test blood sample from said patient who has been administered the coumarin anticoagulant drug, mixing said test plasma sample with plasma that has been made deficient in only factor II and factor X, to provide a corrected plasma sample, which is normal-adjusted in all coagulation factors other than factor II and factor X, wherein the ratio of said test plasma sample and said plasma deficient in only factor II and factor X is in the range from 1:1 to 1:20, adding to said corrected plasma sample one or more coagulation reagents and calcium, determining blood clotting ability of said corrected plasma sample by measuring blood clotting time or thrombin generation, and adjusting the dose of said coumarin anticoagulant drug, to reach recommended a therapeutic INR of about 2 to about 3, such that the dose is increased to maximize the antithrombotic effect of the coumarin drug or the dose is decreased to minimize risk of abnormal bleeding caused by over-anticoagulation.